Neuroscience and Behavioral Physiology

, Volume 50, Issue 1, pp 45–50 | Cite as

The Problem of the Diagnosis and Treatment of Depression by Primary Care Physicians

  • G. P. Kostyuk
  • A. V. MasyakinEmail author
  • L. A. Burygina
  • I. V. Reverchuk

This article addresses the question of the appropriateness of and potential for primary care physicians to diagnose and treat anxious-depressive disorders of nonpsychotic origin in view of their high prevalence for primary care physicians. Arguments are given in favor of a positive answer to this question.


primary medical care nonpsychotic mental disorders anxious-depressive disorders 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. B. Smulevich (ed.), Psychosomatic Disorders in Clinical Practice, MEDpress-Inform, Moscow (2015).Google Scholar
  2. 2.
    V. N. Krasnov, T. V. Dovzhenko, A. E. Bobrov, and E. G. Starostina, “Psychiatry in primary healthcare: a new solution to an old problem,” Sots. Klin. Psikhiatr., 4, 5–13 (2013).Google Scholar
  3. 3.
    WHO, The European Mental Health Action Plan, Problems and Solutions. WHO European Ministerial Conference on Mental Health, Helsinki, Finland, Jan. 12–15, 2005,,-178,788, acc. Oct. 6, 2017.
  4. 4.
    WHO, The European Mental Health Action Plan, Europ. Reg. Committee, 63 session, Chetshe, Izmir, Turkey, Sept. 16–19, 2013,,-98,814, acc. Oct. 6, 2017.
  5. 5.
    M. Copty and D. L. Whitford, “Mental health in general practice: assessment of current state and future needs,” Ir. J. Psychol. Med., 22, No. 3, 83–86 (2005).CrossRefGoogle Scholar
  6. 6.
    R. Kessler, “Mental health care treatment initiation when mental health services are incorporated into primary care practice,” J. Am. Board Fam. Med., 25, No. 2, 255–259 (2012).CrossRefGoogle Scholar
  7. 7.
    E. Van Rijswijk, M. Borghuis, E. van de Lisdonk, et al., “Treatment of mental health problems in general practice: a survey of psychotropics prescribed and other treatments provided,” Int. J. Clin. Pharmacol. Ther., 45, No. 1, 23–29 (2007).CrossRefGoogle Scholar
  8. 8.
    K. Harmon, V. J. Carr, and T. J. Lewin, “Comparison of integrated and consultation-liaison models for providing mental health care in general practice in New South Wales, Australia,” J. Adv. Nurs., 32, No. 6, 1459–1466 (2000).CrossRefGoogle Scholar
  9. 9.
    G. Mitchell, C. Del Mar, and D. Francis, “Does primary medical practitioner involvement with a specialist team improve patient outcomes? A systematic review,” Br. J. Gen Pract., 52, No. 484, 934–939 (2002).PubMedPubMedCentralGoogle Scholar
  10. 10.
    P. S. Wang, P. Berglund, M. Olfson, et al., “Failure and delay in initial treatment contact after fi rst onset of mental disorders in the National Comorbidity Survey Replication,” Arch. Gen. Psychiatry, 62, No. 6, 603–613 (2005).CrossRefGoogle Scholar
  11. 11.
    A. S. Avedisova, “Controlling anxiety symptoms and treating anxiety phobic disorders – is there any alternative,” Psikhiatr. Psikhofarmakoter., 8, No. 5, 3–6 (2006).Google Scholar
  12. 12.
    R. G. Oganov, L. I. Olbinskaya, A. B. Smulevich, et al., “Depression and depressive spectrum disorders in general medical practice. Preliminary results of the KOMPAS program,” Kardiologiya, 1, 48–55 (2004).Google Scholar
  13. 13.
    Yu. A. Aleksandrovsky, Borderline Mental Disorders. Guidelines for Physicians, Moscow (2007), 4th ed.Google Scholar
  14. 14.
    O. P. Vertogradova, “Anxious phobic disorders and depression,” in: Anxiety and Obsessions, A. B. Smulevich (ed.), Scientific Center for Mental Health, Russian Academy of Medical Sciences, Moscow (1998).Google Scholar
  15. 15.
    A. Baranov, I. Denisov, and A. Chuchalin (eds.), Guidelines for Primary Healthcare, GEOTAR-Media, Moscow (2006).Google Scholar
  16. 16.
    I. V. Reverchuk, “Neurotic depression in the Slavs and Finno-Ugrians: nature, culture or illness,” Sovrem. Naukoemk. Tekhnol., 1, 84–88 (2007).Google Scholar
  17. 17.
    M. P. Pignone, B. M. Gaynes, J. L. Rushton, et al., “Screening for Depression in Adults: A Summary of the Evidence for the US Preventive Services Task Force,” Ann. Intern. Med., 136, 765–776 (2002).CrossRefGoogle Scholar
  18. 18.
    S. C. Marcus and M. Olfson, “National trends in the treatment for depression from 1998 to 2007,” Arch. Gen. Psychiatry, 67, No. 12, 1265–1273 (2010), Scholar
  19. 19.
    D. Barlow, Clinical Guidelines for Mental Disorders [Russian translation], Piter, Moscow, St. Petersburg, Nizhnii Novgorod (2008).Google Scholar
  20. 20.
    Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association, Washington, DC (2013), 5th ed.Google Scholar
  21. 21.
    H. C. Schulberg, W. Katon, G. E. Simon, and A. J. Rush, “Treating major depression in primary care practice: an update of the Agency for Health Care Policy and Research Practice Guidelines,” Arch. Gen. Psychiatry, 55, 1121–1127 (1998).CrossRefGoogle Scholar
  22. 22.
    ICD-10: Classification of Mental and Behavioral Disorders. Research Diagnostic Criteria, WHO, Geneva (1994).Google Scholar
  23. 23.
    S. A. Montgomery and J. A. Boer, SSRI in Depression and Anxiety, John Wiley & Sons, Chichester (2011).Google Scholar
  24. 24.
    D. Nutt, K. Rickels, and D. J. Stein, “Generalized Anxiety Disorders: Symptomatology, Pathogenesis and Management, Martin Dunitz, London (2002).CrossRefGoogle Scholar
  25. 25.
    V. Starcevic, Anxiety Disorders in Adults. A Clinical Guide, Oxford Univ. Press, Oxford (2005).Google Scholar
  26. 26.
    D. J. Stein and E. Hollander, Textbook of Anxiety Disorders, American Psychiatric Publishing, Washington (2002).Google Scholar
  27. 27.
    D. Stein, B. Lorer, and St. Stahl, Evidence-Based Psychopharmacology, Cambridge Univ. Press, Cambridge (2005).Google Scholar
  28. 28.
    T. Hayashi and S. M. Stahl, “SIGMA-1 (σ1) receptors and their role in the treatment of affective disorders,” Drugs of the Future, 34, 137–146 (2009).CrossRefGoogle Scholar
  29. 29.
    M. V. Ivanov, “Fluvoxamine: Opportunities in the therapy of psychiatric disorders,” Obozr. Psikhiatr. Med. Psikhol., 4, 91–95 (2012).Google Scholar
  30. 30.
    L. Mandelli et al., “Improvement of cognitive functioning in mood disorder patients with depressive symptomatic recovery during treatment: an exploratory analysis,” Psychiatry Clin. Neurosci., 60, No. 5, 598–604 (2006).CrossRefGoogle Scholar
  31. 31.
    T. Nishimura, T. Ishima, M. Iyo, and K. Hashimoto, “Potentiation of nerve growth factor-induced neurite outgrowth by fluvoxamine: role of sigma-1 receptors, IP3 receptors and cellular signaling pathways,” PLoS One, 3, No. 7, e2558 (2008), publ. online July 2, 2008.CrossRefGoogle Scholar
  32. 32.
    S. Hartter, X. Wang, H. Weigmann, et al., “Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin,” J. Clin. Psychopharmacol., 21, 167–174 (2001).CrossRefGoogle Scholar
  33. 33.
    F. Gatti, L. Bellini, M. Gasperini, et al., “Fluvoxamine alone in the treatment of delusional depression,” Am. J. Psychiatry, 153, 414–416 (1996).CrossRefGoogle Scholar
  34. 34.
    C. Freeman, M. Trimble, and J. Deakin, “Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double- blind, parallel group comparison,” J. Clin. Psychiatry, 55, No. 7, 301–315 (1994).PubMedGoogle Scholar
  35. 35.
    D. H. Barlow and L. A. Campbell, “Mixed anxiety-depression and its implications for models of mood and anxiety disorders,” Compr. Psychiatry, 41, No. 2, Suppl. 1, 55–60 (2000).CrossRefGoogle Scholar
  36. 36.
    G. I. Papakostas and M. Fava, Pharmacotherapy for Depression and Treatment-Resistant Depression, World Sci., Hackensack, NJ (2010).CrossRefGoogle Scholar
  37. 37.
    H. Cramer, R. Lauche, J. Langhorst, and G. Dobos, “Yoga for depression: A systematic review and meta-analysis,” Depress. Anxiety, 30, 1068–1083 (2013).CrossRefGoogle Scholar
  38. 38.
    S. Pampallona, P. Bollini, G. Tibaldi, et al., “Combined pharmacotherapy and psychological treatment for depression: a systematic review,” Arch. Gen. Psychiatry, 61, 714–719 (2004).CrossRefGoogle Scholar
  39. 39.
    W. W. Ishak, K. Ha, N. Kapitanski, et al., “The impact of psychotherapy, pharmacotherapy, and their combination on quality of life in depression,” Harv. Rev. Psychiatry, 19, 277–289 (2011).CrossRefGoogle Scholar
  40. 40.
    M. Raddock, R. Martukovich, E. Berko, et al., “7 tools to help patients adopt healthier behaviors,” J. Fam. Pract., 64, 97–103 (2015).PubMedGoogle Scholar
  41. 41.
    L. G. Castonguay, M. J. Constantino, and M. G. Holtforth, “The working alliance: Where are we and where should we go,” Psychotherapy (Chic.), 43, 271–279 (2006).CrossRefGoogle Scholar
  42. 42.
    R. P. Greenberg, M. J. Constantino, and N. Bruce, “Are patient expectations still relevant for psychotherapy process and outcome,” Clin. Psychol. Rev., 26, 657–678 (2006).CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • G. P. Kostyuk
    • 1
  • A. V. Masyakin
    • 1
    Email author
  • L. A. Burygina
    • 2
  • I. V. Reverchuk
    • 3
  1. 1.Alekseev Psychiatric Clinical Hospital No. 1, Moscow Health DepartmentMoscowRussia
  2. 2.Gannushkin Psychiatric Clinical Hospital No. 4, Moscow Health DepartmentMoscowRussia
  3. 3.Kant Baltic Federal UniversityKaliningradRussia

Personalised recommendations